Business/Financial Results (Form 8-K)

Item 2.02. Results of Operations and Financial Condition.

The information contained in Item 8.01 of this Current Report on Form 8-K (this "Current Report"), to the extent required, is incorporated into this Item 2.02 by reference.

Item 8.01. Other Events.

Nasdaq Matters

On March 9, 2026, Co-Diagnostics, Inc. (the "Company") was formally notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Company has demonstrated compliance with the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the Company's securities will resume trading on Nasdaq effective with the open of the market on March 11, 2026, and the previously disclosed listing matter before the Nasdaq Hearing Panel (the "Panel") has been closed.

The Panel has imposed a Discretionary Panel Monitor for a period of one year, through March 9, 2027. If during the monitoring period, the Company's closing bid price falls below $1.00 per share for 30 consecutive business days, the Company will not be eligible for a 180-day compliance period otherwise available under the Nasdaq Listing Rules. Rather, Nasdaq would issue a delist determination, which the Company could then appeal by requesting a hearing before the Panel. Such request would stay any further action by Nasdaq pending the conclusion of the hearing process.

December 31, 2025 Cash and Cash Equivalents

The Company is providing the following information about its preliminary cash and cash equivalents as of December 31, 2025. Based upon preliminary estimates and currently available information, the Company estimates that its cash and cash equivalents were approximately $11.9 million as of December 31, 2025. This amount is unaudited and preliminary and is subject to completion of the Company's financial closing procedures. As a result, this amount may differ from the amount that will be reflected in the Company's consolidated financial statements as of and for the year ended December 31, 2025.